B38.9 Coccidioidomycosis, unspecified

Name of the Condition

• Coccidioidomycosis, unspecified

Summary

Coccidioidomycosis, unspecified, is a fungal infection caused by Coccidioides species. It primarily affects the lungs but can disseminate to other organs. The condition ranges from asymptomatic or mild respiratory illness to severe, progressive disease, particularly in immunocompromised individuals. The unspecified designation indicates that the clinical details of the presentation are not documented with greater specificity.

Causes

The infection is caused by inhaling airborne spores of Coccidioides fungi, which are endemic to arid regions like the southwestern United States, Mexico, and parts of Central and South America. The fungi thrive in soil and are released into the air during activities that disturb the ground, such as construction or farming.

Risk Factors

• Residence or travel to endemic regions, especially during dry, dusty seasons.
• Occupational exposure to soil (e.g., farmers, construction workers, archaeologists).
• Immunocompromised states, including HIV/AIDS, organ transplantation, or prolonged corticosteroid use.
• Pregnancy, particularly the third trimester.
• Advanced age.

Symptoms

• Fatigue and malaise.
• Cough, chest pain, or shortness of breath.
• Fever, night sweats, or weight loss.
• Joint pain or skin rash (erythema nodosum).
• Severe cases may involve meningitis, bone lesions, or disseminated infection.

Diagnosis

Diagnosis involves clinical evaluation, imaging (e.g., chest X-ray), and laboratory tests such as serology or culture. The unspecified designation may reflect incomplete documentation of the clinical presentation or lack of further specification in the medical record.

Treatment Options

Treatment depends on disease severity and patient factors. Mild cases may resolve without therapy, while moderate to severe infections require antifungal medications (e.g., fluconazole, amphotericin B). Disseminated or severe pulmonary disease often necessitates prolonged treatment.

Prognosis and Follow-Up

Prognosis varies: most immunocompetent individuals recover fully, but immunocompromised patients or those with disseminated disease may have prolonged or recurrent illness. Follow-up includes monitoring for symptom resolution and potential complications, with duration tailored to disease severity.

Complications

• Chronic pulmonary disease (e.g., cavities, fibrosis).
• Disseminated infection (e.g., meningitis, bone lesions).
• Respiratory failure in severe cases.
• Increased risk of recurrence in immunocompromised individuals.

Lifestyle & Prevention

• Avoid exposure to dust in endemic areas (e.g., wear masks during soil-disturbing activities).
• Stay indoors during dust storms.
• Promptly treat underlying immunocompromising conditions.
• Follow local health advisories for high-risk environments.

When to Seek Professional Help

Seek care if symptoms persist (e.g., cough, fever, fatigue) or worsen, especially after travel to endemic regions. Immediate attention is needed for severe symptoms (e.g., difficulty breathing, confusion) or signs of dissemination (e.g., headache, joint pain).

Tips for Medical Coders

Document the clinical presentation thoroughly to support the unspecified designation. Ensure the code aligns with the absence of further specification in the medical record. Verify that the diagnosis is consistent with exposure history or endemic region residency, as this may influence coding accuracy.